Drug Trial Radar · NCT07392892
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
840
Planned (sponsor's estimate)
Start
May 14, 2026
Primary completion
Jul 22, 2031
Study completion Jul 21, 2032
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests. The study has two parts: * In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it. * In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better. The treatment will be given in repeated time periods called cycles.
Conditions
- Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma
- Metastatic Gastric Cancer
- Gastroesophageal Junction Cancer
- Esophageal Adenocarcinoma
Interventions
PF-08634404Biological
Participants will receive PF-08634404 intravenously.
ChemotherapyDrug
Participants will receive PF-08634404 intravenously in combination with Chemotherapy.
NivolumabBiological
Participants will receive Nivolumab intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigatorTime frame: Approximately 4 years
- Phase 2: Number of participants with treatment-emergent adverse eventsTime frame: Through 90 days after the last study intervention; Approximately 4 years
- Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICRTime frame: Approximately 4 years
- Phase 3: Overall Survival (OS)Time frame: Approximately 4 years
Locations
102 sites in 10 countries. Site status is shown where the registry gives one.
UCLA Hematology/Oncology - Atascadero
Atascadero, California · Recruiting
UCLA Hematology/Oncology - Burbank
Burbank, California · Recruiting
UCLA Hematology/Oncology - Encino
Encino, California · Recruiting
UCLA Hematology/Oncology - Marina del Rey
Marina del Rey, California · Recruiting
UCLA Hematology/Oncology - Porter Ranch
Porter Ranch, California · Recruiting
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Not yet recruiting
UCSF Investigational Drugs Pharmacy
San Francisco, California · Not yet recruiting
UCLA Hematology/Oncology - San Luis Obispo
San Luis Obispo, California · Recruiting
UCLA Hematology/Oncology - Santa Barbara
Santa Barbara, California · Recruiting
UCLA Hematology/Oncology - Santa Monica
Santa Monica, California · Recruiting
Rocky Mountain Cancer Centers, LLP
Aurora, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Boulder, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Centennial, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Colorado Springs, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Colorado Springs, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Denver, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Denver, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Englewood, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Lakewood, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Littleton, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Lone Tree, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Longmont, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Pueblo, Colorado · Recruiting
Rocky Mountain Cancer Centers, LLP
Thornton, Colorado · Recruiting
Florida Cancer Specialists
Daytona Beach, Florida · Not yet recruiting
Florida Cancer Specialists
Fleming Island, Florida · Not yet recruiting
Florida Cancer Specialists
Palm Beach Gardens, Florida · Not yet recruiting
Florida Cancer Specialists
Sebring, Florida · Not yet recruiting
Florida Cancer Specialists
Wellington, Florida · Not yet recruiting
Florida Cancer Specialists
West Palm Beach, Florida · Not yet recruiting
Illinois Cancer Specialists
Arlington Heights, Illinois · Recruiting
Illinois CancerCare - Bloomington
Bloomington, Illinois · Recruiting
Illinois Cancer Specialists
Chicago, Illinois · Recruiting
Illinois CancerCare - Galesburg
Galesburg, Illinois · Recruiting
Illinois Cancer Specialists
Niles, Illinois · Recruiting
Illinois CancerCare-Ottawa-Fox River Cancer Center
Ottawa, Illinois · Recruiting
Illinois CancerCare-Pekin
Pekin, Illinois · Recruiting
Illinois CancerCare, P.C.
Peoria, Illinois · Recruiting
Illinois CancerCare-Peru - Valley Regional Cancer Center
Peru, Illinois · Recruiting
Illinois CancerCare-Washington
Washington, Illinois · Recruiting
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.